First elected: 4th July 2024
Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.
These initiatives were driven by Josh MacAlister, and are more likely to reflect personal policy preferences.
MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.
Josh MacAlister has not been granted any Urgent Questions
Josh MacAlister has not been granted any Adjournment Debates
Josh MacAlister has not introduced any legislation before Parliament
Josh MacAlister has not co-sponsored any Bills in the current parliamentary sitting
The Government’s Warm Home Discount (WHD) scheme provides targeted support to eligible low-income households across Great Britain with a £150 rebate off their winter energy bill, the vast majority of which are provided automatically. The WHD scheme provides rebates to pensioners in receipt of Pension Credit Guarantee Credit (Core Group 1) and those in receipt of one of the qualifying means-tested benefits and are living in properties which have an energy cost score, calculated from certain property characteristics, exceeding a high-energy-cost threshold (core Group 2).
In 2023/24 the WHD scheme delivered rebates to 3.14 million households in Great Britain. This represents an increase of around 646 thousand households receiving rebates and an increase of around £97 million of support, compared to 2022/23. Since the WHD scheme began in 2011, over £4 billion in support has been provided to households.
Through the Warm Homes Plan, we will invest an extra £6.6 billion over the next five years in clean heat and energy efficiency, upgrading five million homes through solutions like low carbon heating and improved insulation. We will set out the full details of our Warm Homes Plan, and the approach to Net Zero Buildings more broadly, after the completion of the Spending Review Process.
Through the Warm Homes Plan, we will invest an extra £6.6 billion over the next five years in clean heat and energy efficiency, upgrading five million homes through solutions like low carbon heating and improved insulation. We will set out the full details of our Warm Homes Plan, and the approach to Net Zero Buildings more broadly, after the completion of the Spending Review Process.
Yes, the Nuclear Decommissioning Authority has sought, and received, approval for the purchase of land in West Cumbria in the last ten years. This includes land parcels adjacent to the Low Level Waste Repository at Drigg.
Yes, requests have been made, within the last ten years, to access the land at Moorside for the purpose of undertaking detailed assessment of its suitability to be used for the development of new nuclear power generation infrastructure. These requests have been granted by the Nuclear Decommissioning Authority.
New nuclear National Policy Statement (EN-7) is being developed to provide updated planning guidance to developers. This will be subject to the usual public consultation and Parliamentary scrutiny. The potential sites listed in EN-6 are likely to retain many inherent advantages and it is for those landowners to decide how to manage their assets. For those sites within the wider government estate, optimal land use will be considered to best maximise public benefit.
A new nuclear National Policy Statement (EN-7) is being developed which will provide updated planning guidance and set out any specific assessment criteria for the siting of new nuclear power stations.
Government will always consider strategic land use opportunities for its estate and is committed to managing its land to best maximise public benefit.
The New nuclear National Policy Statement (EN-7) is being developed to provide updated planning guidance to developers. This will be subject to the usual public consultation and Parliamentary scrutiny. The potential sites listed in EN-6 are likely to retain many inherent advantages and it is for those landowners to decide how to manage their assets. For those sites within the wider government estate, optimal land use will be considered to best maximise public benefit.
Great British Nuclear, the Department’s arm’s-length body responsible for helping deliver the Government’s nuclear programme, is currently running a small modular reactor technology selection process for UK deployment. The window for submitting tenders has closed and Great British Nuclear is evaluating bids. This is a complex procurement, and it is important Great British Nuclear ensures a fair and robust process that delivers sustainable outcomes. Further updates will be made on this, as well as setting out plans for associated sites, in due course.
To date, no decisions have been made, but discussions are ongoing regarding the most effective use of the land at Moorside. The Department is considering options to maximise public benefit.
Insurance Type | Jan-Dec 2023 |
Travel | £25,511.75 |
Building | £30,261.73 |
Vehicle | £121,806.69 |
| £177,580.17 |
Average number of employees: 1,229.
Average number of Coastguard Rescue Officers (CROs): 3,080.
Insurance premiums within the MCA cover all employees and CROs as applicable. Insurance premiums are not split by business activity.
In late 2020, NHS England launched a series of public consultations seeking views on proposals to amend the responsibilities for the prescribing, supply, and administration of medicines for the following professionals:
This work was undertaken as part of the Chief Professions Officers’ Medicines Mechanisms (CPOMM) programme. The Department is working with NHS England to consider the CPOMM’s consultations and progress the extension of responsibilities to supply, administer, or prescribe medicines under the Human Medicines Regulations 2012 (HMRs 2012) to regulated healthcare professionals, where a clear need and benefits have been identified.
For example, the Department recently completed work to amend the HMRs 2012 to allow dental hygienists and dental therapists to supply and administer specified medicines via exemptions, and pharmacy technicians to use Patient Group Directions. This legislation came into force in late June 2024. The Department will review priorities for progressing work in the CPOMM programme.
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT) used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply whilst stocks are limited.
The Department has also been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are also impacting countries throughout Europe. As a result of intensive work, some issues have been resolved. All strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available. We are working to resolve the remaining issues impacting some strengths of methylphenidate. This includes asking suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term.
The Department has worked with specialist clinicians to develop management advice for clinicians which includes consideration to prescribe available alternative brands of methylphenidate prolonged release tablets. We have widely disseminated our communications and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping to ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.
The build of the Croasdale Extended Area Services (EAS) mast was completed in November 2023. Since then work has been underway to complete power and network connections to the mast, and it is now envisaged that all Mobile Network Operators (MNOs), as part of the Shared Rural Network programme, will be able to activate their services by end of July 2025.